Genomic Characterization of Upper Tract Urothelial Carcinoma

European Urology

Volumn 68, Issue 6, 2015, Pages 970-977

  Sfakianos, John P ^a,b   Cha, Eugene K ^a   Iyer, Gopa ^a,c   Scott, Sasinya N ^a   Zabor, Emily C ^a   Shah, Ronak H ^a   Ren, Qinghu ^a   Bagrodia, Aditya ^a   Kim, Philip H ^a   Hakimi, A Ari ^a   Ostrovnaya, Irina ^a   Ramirez, Ricardo ^a   Hanrahan, Aphrothiti J ^a   Desai, Neil B ^a   Sun, Arony ^a   Pinciroli, Patrizia ^a,d   Rosenberg, Jonathan E ^a,c   Dalbagni, Guido ^a,c   Schultz, Nikolaus ^a   Bajorin, Dean F ^a,c   Reuter, Victor E ^a,c   Berger, Michael F ^a,c   Bochner, Bernard H ^a,c   Al Ahmadie, Hikmat A ^a   Solit, David B ^a,c   Coleman, Jonathan A ^a,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bladder cancer; Genomics; Targeted therapy; Upper tract urothelial carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; COPY NUMBER VARIATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NEXT GENERATION SEQUENCING; ONCOGENE H RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; COMPARATIVE STUDY; GENETICS; GENOMICS; KIDNEY TUMOR; MIDDLE AGED; MUTATION; URETER TUMOR;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENOMICS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84983171153     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.07.039     Document Type: Article

References (28)

1. J.J. Munoz, and L.M. Ellison Upper tract urothelial neoplasms: incidence and survival during the last 2 decades J Urol 164 2000 1523 1525
2. S. Olgac, M. Mazumdar, G. Dalbagni, and V.E. Reuter Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases Am J Surg Pathol 28 2004 1545 1552
3. G.D. Stewart, S.V. Bariol, K.M. Grigor, D.A. Tolley, and S.A. McNeill A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract BJU Int 95 2005 791 793
4. J.W. Catto, D.R. Yates, I. Rehman, and et al. Behavior of urothelial carcinoma with respect to anatomical location J Urol 177 2007 1715 1720
5. V. Margulis, S.F. Shariat, S.F. Matin, and et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration Cancer 115 2009 1224 1233
6. E.K. Cha, S.F. Shariat, M. Kormaksson, and et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma Eur Urol 61 2012 818 825
7. M. Rink, B. Ehdaie, E.K. Cha, and et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery Eur Urol 62 2012 677 684
8. M. Roupret, A.R. Azzouzi, and O. Cussenot Microsatellite instability and transitional cell carcinoma of the upper urinary tract BJU Int 96 2005 489 492
9. J.W. Catto, A.R. Azzouzi, I. Rehman, and et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma J Clin Oncol 23 2005 2903 2910
10. J.M. van Oers, E.C. Zwarthoff, I. Rehman, and et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours Eur Urol 55 2009 650 657
11. P.H. Kim, E.K. Cha, J.P. Sfakianos, and et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder Eur Urol 67 2015 198 201
12. D.T. Cheng, T.N. Mitchell, A. Zehir, and et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology J Mol Diagn 17 2015 251 264
13. A. McKenna, M. Hanna, E. Banks, and et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data Genome Res 20 2010 1297 1303
14. H.H. Won, S.N. Scott, A.R. Brannon, R.H. Shah, and M.F. Berger Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing J Vis Exp 2013 e50710
15. T. Rausch, T. Zichner, A. Schlattl, A.M. Stutz, V. Benes, and J.O. Korbel DELLY: structural variant discovery by integrated paired-end and split-read analysis Bioinformatics 28 2012 i333 i339
16. E. Cerami, J. Gao, U. Dogrusoz, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
17. N. Cancer Genome Atlas Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
18. E.D. Pleasance, R.K. Cheetham, P.J. Stephens, and et al. A comprehensive catalogue of somatic mutations from a human cancer genome Nature 463 2010 191 196
19. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
20. Y. Gui, G. Guo, Y. Huang, and et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat Genet 43 2011 875 878
21. G. Guo, X. Sun, C. Chen, and et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation Nat Genet 45 2013 1459 1463
22. S.V. Williams, C.D. Hurst, and M.A. Knowles Oncogenic FGFR3 gene fusions in bladder cancer Hum Mol Genet 22 2013 795 803
23. Y.M. Wu, F. Su, S. Kalyana-Sundaram, and et al. Identification of targetable FGFR gene fusions in diverse cancers Cancer Discov 3 2013 636 647
24. G. Iyer, H. Al-Ahmadie, N. Schultz, and et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer J Clin Oncol 31 2013 3133 3140
25. H.A. Al-Ahmadie, G. Iyer, M. Janakiraman, and et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma J Pathol 224 2011 270 279
26. A.A. Bakkar, H. Wallerand, F. Radvanyi, and et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108 8112
27. E. Lopez-Knowles, S. Hernandez, N. Malats, and et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors Cancer Res 66 2006 7401 7404
28. D. Lindgren, G. Sjodahl, M. Lauss, and et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma PLoS One 7 2012 e38863